Zeng Z - Search Results

1

Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome.

Xiang Z, Zeng Z, Tang Z, Fan J, Sun H, Wu W, Tan Y. Xiang Z, et al. Among authors: zeng z. Cancer J. 2009 Nov-Dec;15(6):519-25. doi: 10.1097/PPO.0b013e3181c6aa6b. Cancer J. 2009. PMID: 20010172

2

Observation of changes in peripheral T-lymphocyte subsets by flow cytometry in patients with liver cancer treated with radioimmunotherapy.

Zeng ZC, Tang ZY, Liu KD, Yu YQ, Yang BH, Cai XJ, Xie H, Cao SL. Zeng ZC, et al. Nucl Med Commun. 1995 May;16(5):378-85. doi: 10.1097/00006231-199505000-00010. Nucl Med Commun. 1995. PMID: 7659390 Clinical Trial.

3

Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection.

Tang ZY, Yu YQ, Zhou XD, Ma ZC, Yang BH, Lin ZY, Lu JZ, Liu KD, Fan Z, Zeng ZC. Tang ZY, et al. Among authors: zeng zc. World J Surg. 1995 Jan-Feb;19(1):47-52. doi: 10.1007/BF00316979. World J Surg. 1995. PMID: 7740810

4

Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-labeled Hepama-1 mAb. Preliminary results and discussion.

Zeng ZC, Tang ZY, Liu KD, Lu JZ, Cai XJ, Xie H. Zeng ZC, et al. Cancer Immunol Immunother. 1994 Nov;39(5):332-6. doi: 10.1007/BF01519987. Cancer Immunol Immunother. 1994. PMID: 7987865 Free PMC article.

5

Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: preliminary results.

Zeng ZC, Tang ZY, Xie H, Liu KD, Lu JZ, Chai XJ, Wang GF, Yao Z, Qian JM. Zeng ZC, et al. J Cancer Res Clin Oncol. 1993;119(5):257-9. doi: 10.1007/BF01212721. J Cancer Res Clin Oncol. 1993. PMID: 8382704 Clinical Trial.

6

Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials.

Zeng ZC, Tang ZY, Liu KD, Lu JZ, Xie H, Yao Z. Zeng ZC, et al. J Cancer Res Clin Oncol. 1998;124(5):275-80. doi: 10.1007/s004320050166. J Cancer Res Clin Oncol. 1998. PMID: 9645459 Clinical Trial.

7

Phase I clinical trial of oral furtulon and combined hepatic arterial chemoembolization and radiotherapy in unresectable primary liver cancers, including clinicopathologic study.

Zeng ZC, Tang ZY, Wu ZQ, Ma ZC, Fan J, Qin LX, Zhou J, Wang JH, Wang BL, Zhong CS. Zeng ZC, et al. Am J Clin Oncol. 2000 Oct;23(5):449-54. doi: 10.1097/00000421-200010000-00004. Am J Clin Oncol. 2000. PMID: 11039502 Clinical Trial.

8

DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line.

Zeng ZC, Jiang GL, Wang GM, Tang ZY, Curran WJ, Iliakis G. Zeng ZC, et al. World J Gastroenterol. 2002 Oct;8(5):797-803. doi: 10.3748/wjg.v8.i5.797. World J Gastroenterol. 2002. PMID: 12378618 Free PMC article.

9

Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma.

Zeng ZC, Tang ZY, Yang BH, Liu KD, Wu ZQ, Fan J, Qin LX, Sun HC, Zhou J, Jiang GL. Zeng ZC, et al. Eur J Nucl Med Mol Imaging. 2002 Dec;29(12):1657-68. doi: 10.1007/s00259-002-0996-x. Epub 2002 Oct 3. Eur J Nucl Med Mol Imaging. 2002. PMID: 12458401

10

Radiation therapy for the locoregional lymph node metastases from hepatocellular carcinoma, phase I clinical trial.

Zeng ZC, Tang ZY, Yang BH, Fan J, Qin LX, Jiang GL, Zhou J, Sun HC, Cheng JM, Wang JH. Zeng ZC, et al. Hepatogastroenterology. 2004 Jan-Feb;51(55):201-7. Hepatogastroenterology. 2004. PMID: 15011864 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,012 results

Search Page

Filters